Filtered By:
Specialty: Research
Condition: Atrial Fibrillation
This page shows you your search results in order of date. This is page number 15.
Order by Relevance | Date
Total 257 results found since Jan 2013.
Strategies for improving dabigatran adherence for stroke prevention in patients with non-valvular atrial fibrillation: education and drug intake reminders (FACILITA study).
CONCLUSIONS: A mixed intervention, consisting of patient education and a simple calendar reminder of drug intake, is an effective strategy to improve dabigatran therapeutic adherence in patients with NVAF. The percentage of adherence with dabigatran was high.
PMID: 29384410 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - February 1, 2018 Category: Research Tags: Curr Med Res Opin Source Type: research
Impact of medication adherence on risk of ischemic stroke, major bleeding, and deep vein thrombosis in atrial fibrillation patients using novel oral anticoagulants.
CONCLUSION: Adherence to NOACs for both 6 months and continued prolong use (up to 12-months) was associated with a reduction in IS and DVTPE risk, but did not substantially increase risk of MB. Further studies on newer, individual NOACs and older population are warranted.
PMID: 29334815 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - January 18, 2018 Category: Research Tags: Curr Med Res Opin Source Type: research
Treatment and discharge patterns among patients hospitalized with non-valvular atrial fibrillation transitioning from the inpatient to outpatient setting.
CONCLUSIONS: Most patients hospitalized for NVAF were discharged to home support, and the majority did not have OAC treatment during hospitalization or the 30 days post-discharge. Additional investigation should be conducted on trends beyond 30 days post hospitalization and the reasons for not receiving anticoagulation therapy in patients at moderate to severe risk of stroke or systemic embolism. Helping to avoid preventable strokes is an important goal for public health.
PMID: 29235900 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - December 15, 2017 Category: Research Tags: Curr Med Res Opin Source Type: research
Pradaxa ® (dabigatran etexilate) now approved in more than 100 countries for stroke prevention in atrial fibrillation
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news
Implications of stroke and bleeding risk-scores and comorbidities on episode-based bundled payments for patients with nonvalvular atrial fibrillation.
CONCLUSION: NVAF patients accrue variable healthcare costs. Stroke and bleeding risk should be taken into account during the creation of NVAF payment bundles.
PMID: 29164990 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - November 23, 2017 Category: Research Tags: Curr Med Res Opin Source Type: research
The Benefits of Exercise Training on Aerobic Capacity in Patients with Heart Failure and Preserved Ejection Fraction.
Authors: do Prado DML, Rocco EA
Abstract
Heart failure with preserved ejection fraction (HFpEF) is defined as an inability of the ventricles to optimally accept blood from atria with blunted end- diastolic volume response by limiting the stroke volume and cardiac output. The HEpEF prevalence is higher in elderly and women and may be associated to hypertension, diabetes mellitus and atrial fibrillation. Severe exercise intolerance, manifested by dyspnea and fatigue during physical effort is the important chronic symptom in HFpEF patients, in which is the major determinant of their reduced quality of life. In this se...
Source: Advances in Experimental Medicine and Biology - November 5, 2017 Category: Research Tags: Adv Exp Med Biol Source Type: research
Real world adherence to oral anticoagulant in non-valvular atrial fibrillation patients in China.
CONCLUSION: Oral anticoagulation was significantly underused in NVAF patients in China. Age, sex, concurrent drug usage and disease history were associated factors. Improving warfarin adherence was promising to reduce ischemic stroke risk of NVAF patients.
PMID: 29022745 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - October 13, 2017 Category: Research Tags: Curr Med Res Opin Source Type: research
Outcomes associated with warfarin time in therapeutic range among US veterans with nonvalvular atrial fibrillation.
CONCLUSIONS: The observed quality of warfarin control in VA EMR suggests room for improvement given the association with elevated risk of adverse clinical outcomes.
PMID: 28945114 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - September 27, 2017 Category: Research Tags: Curr Med Res Opin Source Type: research
Cost-effectiveness analysis of dabigatran versus rivaroxaban for stroke prevention in patients with non-valvular atrial fibrillation using real-world evidence in elderly US Medicare beneficiaries.
CONCLUSIONS: In this study using US Medicare real-world data, dabigatran was found to dominate rivaroxaban. The analyses were limited by the short follow-up period of the real-world data and results may not be generalizable to other patient populations.
PMID: 28862479 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - September 3, 2017 Category: Research Tags: Curr Med Res Opin Source Type: research
Comparison of effectiveness and safety of treatment with apixaban vs. other oral anticoagulants among elderly nonvalvular atrial fibrillation patients.
CONCLUSIONS: In the real-world setting after controlling for differences in patient characteristics, apixaban is associated with significantly lower risk of S/SE and MB than rivaroxaban and warfarin, and a trend towards better outcomes vs. dabigatran among elderly NVAF patients in the US.
PMID: 28849676 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - August 31, 2017 Category: Research Tags: Curr Med Res Opin Source Type: research
Potential Biological Markers of Atrial Fibrillation: A Chance to Prevent Cryptogenic Stroke.
Abstract
Stroke affects millions of people all over the world, causing death and disability. The most frequent type of this disease is ischemic stroke, which can be caused by different factors. In approximately 25 percent of cases, no obvious cause can be found. Recent observations have shown that paroxysmal atrial fibrillation could be responsible for a significant number of cryptogenic stroke events. Short- or long-lasting ECG monitoring could help with the diagnosis of transient arrhythmias. Unfortunately, these techniques either are expensive or require good patient compliance. An alternative option is the ide...
Source: Biomed Res - August 9, 2017 Category: Research Authors: Szegedi I, Szapáry L, Csécsei P, Csanádi Z, Csiba L Tags: Biomed Res Int Source Type: research
Quantifying the relative importance to patients of avoiding symptoms and outcomes of heart failure.
CONCLUSIONS: Patients' preferences for avoiding HF outcomes vary across outcomes and by individuals' knowledge, caregiver status, and age. Health care providers should solicit and incorporate insights about patients' knowledge of HF and their preference for avoiding HF outcomes into HF education and management planning efforts.
PMID: 28704074 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - July 15, 2017 Category: Research Tags: Curr Med Res Opin Source Type: research
Comparing the economic burden of ischemic stroke patients with and without atrial fibrillation: a retrospective study in Beijing, China.
CONCLUSIONS: AF increased the use of healthcare resources, treatment cost, and economic burden in patients with IS. Therefore, prevention of cardio-embolic events patients with AF by anticoagulants may decrease the economic burden in patients with IS.
PMID: 28657348 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - June 29, 2017 Category: Research Tags: Curr Med Res Opin Source Type: research
Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran, or rivaroxaban compared with warfarin in the United States Medicare population.
CONCLUSIONS: Among the DOACs in the study, only apixaban is associated with a significantly lower risk of stroke/SE and major bleeding and lower related medical costs compared to warfarin.
PMID: 28635338 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - June 22, 2017 Category: Research Tags: Curr Med Res Opin Source Type: research
Impact of renal function on ischemic stroke and major bleeding rates in nonvalvular atrial fibrillation patients treated with warfarin or rivaroxaban: a retrospective cohort study using real-world evidence.
CONCLUSIONS: Ischemic stroke rates were significantly lower in the overall NVAF population for rivaroxaban vs warfarin users, including patients with eCrCl below 50 mL/min. For all renal function groups, major bleeding risks were not statistically different between treatment groups.
PMID: 28590785 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - June 8, 2017 Category: Research Tags: Curr Med Res Opin Source Type: research
